Discovering Dermatology Times: July 2024 Print

This year, the July issue of Dermatology Times marks an important milestone as Dermatology Times celebrates its 45th anniversary. In this issue, readers will find a breakdown of dermatology milestones over the past 45 years, as well as insights into dermatology's evolution from our Editorial Advisory Board members. Additionally, this issue includes a collection of thought-provoking articles and topics ranging from addressing sunscreen safety to highlights from 6 presenters from the 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference. Be sure to read the highlights from the issue below. Also, don’t miss a moment of Dermatology Times by signing up for our eNewsletters and subscribing to receive the free print issue and supplement each month.

Addressing Sunscreen Safety: A Review of EWG’s 2024 Guide to Sunscreens

Recent findings from the Environmental Working Group (EWG) highlighted potential shortcomings in sunscreens available in the US market. The organization’s 2024 Guide to Sunscreens reported that only one-fourth of approximately 1700 SPF products meet the criteria for adequate sun protection, further underlining differences in regulatory processes in the US, Europe, and other parts of the world.

Moreover, EWG reported that approximately 1700 studied sunscreens still contain ingredients that pose potential health risks, including oxybenzone, octinoxate, homosalate, octisalate, and avobenzone. Most of these ingredients have exhibited prior evidence of skin penetration and skin allergy or other concerns. Titanium dioxide and zinc oxide are currently the only proposed safe and effective active ingredients in sunscreens.

Dermatology Times recently spoke with Adewole Adamson, MD, MPP, a board-certified dermatologist based in Austin, Texas, and an assistant professor in the Department of Internal Medicine (Division of Dermatology) at Dell Medical School at the University of Texas at Austin. Adamson is also a health services researcher and specializes in caring for patients at high risk for melanoma of the skin, evidence-based medicine, and health policy.

Continue reading

Commemorating Dermatology Times’ 45th Anniversary

As Dermatology Times celebrates its 45th anniversary, we invite you to join us on a journey through the most impactful milestones in dermatology’s history. Over the decades, advancements in clinical practices, groundbreaking treatments, and innovative technologies have revolutionized the specialty, benefiting both practitioners and patients alike. In this special edition, we gain invaluable insights from our esteemed editorial advisory board on the influential people, pivotal drugs, and cutting-edge technologies that have shaped dermatology.

460-370 BC

Hippocrates, often called the father of modern medicine, proposes classifying skin diseases and treated them with honey, tar, and fats, based on humoral theory.

1836

Henry Daggett Bulkley, MD, the first US dermatologist, opened the Broome Street Infirmary for Diseases of the Skin in New York, New York.

1865

Alexander John Balmanno Squire used photography for the first time to document skin diseases.

1893

Niels Ryberg Finsen pioneered the use of UV radiation for treating lupus vulgaris, winning the Nobel Prize in Medicine in 1903.

Continue reading

Rapid HS Pearls: Drug Data and Wound Care

Managing hidradenitis suppurativa (HS) requires a multifaceted approach with medical surgical, and social interventions to serve patients, and 4 leaders in HS research and treatment showcased the latest drugs and treatment strategies at the 2024 Fall Clinical Dermatology Conference for Physician Assistants and Nurse Practitioners in Scottsdale, Arizona. The workshop titled “A Clinician’s Guide to Managing HS” was led by Hadar Lev-Tov, MD, MAS, associate professor at the University of Miami Miller School of Medicine in Miami, Florida; Jennifer Hsiao, MD, associate professor at the Keck School of Medicine at the University of Southern California in Los Angeles, California; TJ Chao, MPAS, PA-C, advanced practitioner at Atlanta North Dermatology in Atlanta, Georgia; and Athena Gierbolini, HS Foundation board member, Hope for HS president.

Session leaders took a moment to pause for perspective on diagnosing HS. They remind clinicians of the 2-2-6 Rule: 2 episodes of 2 or more abscesses in 6 months. Comorbidities that are level II evidence for HSto screen for include acne, pilonidal disease, depression, suicidality, anxiety, sexual dysfunction tobacco or substance use, dyslipidemia T2D, HTN, obesity, PCOS, inflammatory bowel disease, and spondyloarthirits.

Continue reading

Top Insights From 6 Influential Leaders in AD

The summer conference spotlighting atopic dermatitis (AD) late-breakers and insights transitioned from Revolutionizing Atopic Dermatitis (RAD) to Revolutionizing Alopecia Areata, Vitiligo, and Eczema (RAVE) in Chicago, Illinois, this year. Six AD management and research leaders shared dozens of pearls to equip dermatology clinicians with the latest treatment advancements, guideline updates, and more.

Raj Chovatiya, MD, PhD, MSCI, clinical associate professor at the Rosalind Franklin University of Medicine and Science’s Chicago Medical School in Illinois, founder and director of the Center for Medical Dermatology and Immunology Research in Chicago, and Dermatology Times’ 2024 Fall Editor in Chief, highlighted the progress in treating itch in AD and explored the potential for current therapeutics to achieve remission. Chovatiya emphasized that itch is a major concern for patients with AD and noted that recent advances allow for better measurement and treatment.

Continue reading

Click here to view all articles

Click here to read the full issue